OTHER
Therapeutics
Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation
| The first 150 words of the full text of this article appear below. |
individual patient data meta-analysis of 12 randomised controlled trials (RCTs). 6 RCTs were placebo-controlled; 8 RCTs compared an oral anticoagulant (OAC) with an antiplatelet (AP).
outcome adjudication committee was blinded in 11 trials.
8932 adults (mean age 72 y, 63% men) with non-valvular atrial fibrillation. Patients with clinical indications for or against any of the active therapies were excluded.
full-dose OACs (mainly warfarin sodium or 4-hydroxycoumarin) with lower target international normalised ratio (INR) of 1.5–2.8 and upper target INR of 2.7–4.2 (n = 3430); APs (mainly acetylsalicylic acid, 75–325 mg) with or without low-dose OACs (median INR <1.5; n = 3531); or placebo (n = 1971).
ischaemic stroke, serious bleeding, and cardiovascular events (ischaemic stroke, myocardial infarction, systemic embolism, or vascular death). Intention-to-treat analysis.
mean 2 years.
Older age was associated with increased risk of all outcomes (table). Independent of age and other covariates, both OACs and APs decreased
Mount Sinai School of Medicine, New York, New York, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
